Abstract
The advent of perpetuating living organoids derived from patient tissue is a promising avenue for cancer research but is limited by difficulties with precise characterization. In this brief communication, we demonstrate via time-lapse imaging distinct phenotypes of prostate organoids derived from patient material– without confirmation of cellular identity. We show that organoids derived from histologically normal tissue more readily spread on a physiologic extracellular matrix (ECM) than on pathologic ECM (p<0.0001), while tumor-derived organoids spread equally on either substrate (p=0.2406). This study is an important proof-of-concept to defer precise characterization of organoids and still glean information into disease pathology.
1 Introduction
Patient-derived organoids (PDOs) provide a method for investigating human prostate cancer cells in culture in three dimensions. There remains a paucity of biobanked low to intermediate-grade PDOs. This is due, in part, to difficulty in confirming cell(s)-of-origin, and this cancer’s slow-growing nature leads to low yield sample volumes when grown from needle biopsies (1). The goal of this study was to define distinct phenotypes of prostate PDOs grown from tumor or normal samples without regard to the identity of the cells within the final organoids. Our approach was to investigate the phenotypic behavior of living organoids, obtained using needle biopsies from gross normal and prostate cancer tissue, when exposed to physiologically relevant extracellular matrix (ECM) proteins. Prostate tumors undergo ECM composition change, budding through areas of basal cell-secreted Laminin-332 loss to migrate along nerves and stroma that are rich in Laminin-511 (2, 3). Through this route, the cancer escapes the gland and accesses the lymph nodes, pelvic skeleton, and vertebral spine (4, 5). We hypothesize that these early cell-ECM interactions can provide prognostic indications of prostate tumor behavior before it escapes its primary site. Here, we utilize digital image analysis via a 3D video imaging system to directly observe and record morphologic transformations of the organoids within 21 days post-explant.
2 Methods
2.1 Patient cohort
Fresh biospecimens from men treated at Banner University Medical Center (Tucson, AZ) were procured under IRB approval. The cohort included only hormone-naïve prostate cancer patients with localized disease who underwent robotic radical prostatectomy (RP) as part of the standard of care. Informed consent was obtained for all patients. Samples and redacted pathology reports were biobanked in the University of Arizona Tissue Acquisition and Cellular/Molecular Analysis Shared Resource. All were stripped of personal health information and identifiers.
2.2 Organoids
Needle cores from fresh RP specimens were harvested at the time of surgery. Both the primary tumor and non-diseased regions of the prostate were sampled based on gross morphology so that each tumor sample has a matched normal control. Repeat needle cores histologically confirmed gross morphology. PDOs were processed as described in (6). 3D culture of RWPE1 spheroids was performed as described in (7).
2.3 Live imaging
Glass-bottom dishes (MatTek P35G-1.5-14-C) were coated with Laminin-332 or Laminin-511 as described in (8). Organoids were isolated from Matrigel by pipetting up and down with a wide-bore tip and centrifuging 400xG for 5min, then plated on the pre-coated dishes. Time-lapse images were acquired every hour for up to 24hr on a Nikon Eclipse Ti2-E in a regulated environmental chamber set to 37°C, 21% O2, 5% CO2, then processed into binary masks for analysis using ImageJ and GraphPad Prism 8. Spreading is estimated by C = 4*pi*A/P^2, where C is circularity, A is area and P is perimeter. We defined “spread” as C < 0.60.
3 Results
Our institution derived organoids from needle core samples of primary tumors and matched normal tissue from 56 prostate cancer patients. For the current study we chose organoids from three patients whose tumors exhibited similar pathology (Grade Group II, pT3aN0). We measured PDO spreading onto two ECM proteins: Laminin-332, normally secreted by prostate basal epithelial cells, and Laminin-511, which coats smooth muscle cells and nerve axons within the gland (2). Average circularity (C) over time was fitted to a nonlinear curve as a proxy for spreading. Circularity curves are significantly different for normal-derived organoids depending on their substrate, with an average time to spreading of 8.37hr on Laminin-332 and 14.29hr on Laminin-511 when interpolated using C=0.60 (p<0.0001). Interestingly, curves of tumor-derived organoids do not differ between substrates, time to spreading is 9.49hr on Laminin-332 and 8.64hr on Laminin-511 (p=0.2406) (Figure 1; Figure S1). We compared the above results to laboratory-generated prostate spheroids grown from RWPE1, a nontumorigenic, immortalized line derived from epithelial cells of a histologically normal adult human prostate (9). The behavior of RWPE-1 spheroids mirrored that of the normal-derived PDOs by spreading more quickly on Laminin-332 (4.49hr) compared to Laminin-511 (8.91hr, p<0.0001).
Figure 1
4 Discussion
We show that the transition from the mature glandular structure of the organoid to a state of heightened cell motility and escape is influenced by the composition of the available ECM, whereas normal-derived organoids spread more quickly on Laminin-332 (Supplementary Movie 1), the isoform encountered in intact prostate glands, than on the stromal isoform Laminin-511 (Supplementary Movie 2). In contrast, tumor-derived organoids display no ECM preference, likely reflecting their adaptation to the stromal microenvironment. It will be interesting to correlate invasive behavior to the clinicopathologic grading and staging of the primary neoplasm. We predict that organoids derived from higher grade tumors will spread more readily on Laminin-511, reflective of their propensity to invade through the smooth muscle stroma along nerves to escape the prostate gland (4, 5). We further predict this to correlate to metastatic potential, as local invasion precedes extra-prostatic extension.
Characterization of organoids is an ongoing barrier to performing rapid and cost-effective studies utilizing this powerful biological system. This study demonstrates the intriguing possibility of gleaning information on tumor behavior without the need for costly analyses to confirm cell-of-origin. We assert that measurable phenotypic differences are perceptible whether the origin of tumor-derived organoids is truly a cancer cell or neighboring healthy cell. We believe that this approach with be a boon towards understanding early aggressive events that dictate disease outcomes.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by Institutional Review Board - The University of Arizona Human Subjects Protection Program. The patients/participants provided their written informed consent to participate in this study.
Author contributions
KM, NI, KB, AC, and BL jointly conceptualized the project. NI, GP, and BL generated the organoid material used in this project. KM performed experiments and generated the data used in this manuscript with technical assistance from NI and NW, KM drafted this manuscript, with edits and review provided by all co-authors. All authors contributed to the article and approved the submitted version.
Funding
KM work has been funded by the NIH F30 CA247106 and the ARCS Foundation Phoenix Chapter. AC work has been funded by the NIH R01 CA242226 and the DoD W81XWH-19-1-0455. NI work has been funded by the NIH P30 CA023074. NW work has been funded by the DoD W81XWH-19-1-0455.
Acknowledgments
We thank the Tissue Acquisition and Cellular/Molecular Analysis Core Resource (TACMASR) and The University of Arizona Institutional Review Board. This work could not have been done without their support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.1083150/full#supplementary-material
References
1
BoseSCleversHShenX. Promises and challenges of organoid-guided precision medicine. Med (2021) 2(9):1011–26. doi: 10.1016/j.medj.2021.08.005
2
NagleRBCressAE. Metastasis update: Human prostate carcinoma invasion via tubulogenesis. Prostate Cancer 2011. (2011) p:249290. doi: 10.1155/2011/249290
3
BrarPKDalkinBLWeyerCSallamKVirtanenINagleRB. Laminin alpha-1, alpha-3, and alpha-5 chain expression in human prepubertal [correction of prepubetal] benign prostate glands and adult benign and malignant prostate glands. Prostate (2003) 55(1):65–70. doi: 10.1002/pros.10206
4
PenningtonJWPrentissRJHoweG. Radical prostatectomy for cancer: Significance of perineural lymphatic invasion. J Urol (1967) 97(6):1075–7. doi: 10.1016/S0022-5347(17)63180-X
5
ZarebaPFlavinRIsikbayMRiderJRGerkeTAFinnSet al. Perineural invasion and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2017) 26(5):719–26. doi: 10.1158/1055-9965.EPI-16-0237
6
DrostJKarthausWRGaoDDriehuisESawyersCLChenYet al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc (2016) 11(2):347–58. doi: 10.1038/nprot.2016.006
7
WangMNagleRBKnudsenBSRogersGCCressAE. A basal cell defect promotes budding of prostatic intraepithelial neoplasia. J Cell Sci (2017) 130(1):104–10. doi: 10.1242/jcs.188177
8
SrokaICChenMLCressAE. Simplified purification procedure of laminin-332 and laminin-511 from human cell lines. Biochem Biophys Res Commun (2008) 375(3):410–3. doi: 10.1016/j.bbrc.2008.08.029
9
BelloDWebberMMKleinmanHKWartingerDDRhimJS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis (1997) 18(6):1215–23. doi: 10.1093/carcin/18.6.1215
Summary
Keywords
organoids, prostate cancer, video microscopy, cancer phenotypes, extracellular matrix
Citation
Marr KD, Ignatenko NA, Warfel NA, Batai K, Cress AE, Pollock GR, Wong AC and Lee BR (2023) Digital image analysis using video microscopy of human-derived prostate cancer vs normal prostate organoids to assess migratory behavior on extracellular matrix proteins. Front. Oncol. 12:1083150. doi: 10.3389/fonc.2022.1083150
Received
28 October 2022
Accepted
28 December 2022
Published
13 January 2023
Volume
12 - 2022
Edited by
Mauro Sergio Pavao, Federal University of Rio de Janeiro, Brazil
Reviewed by
Magaly Martinez-Ferrer, University of Puerto Rico, Puerto Rico; Mark Emberton, University College London, United Kingdom
Updates
Copyright
© 2023 Marr, Ignatenko, Warfel, Batai, Cress, Pollock, Wong and Lee.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Benjamin R. Lee, brlee@urology.arizona.edu
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.